ABSTRACT
OBJECTIVES: Clinical outcome assessment (COA) developers must ensure that measures assess aspects of health that are meaningful to the target patient population. Although the methodology for doing this is well understood for certain COAs, such as patient-reported outcome measures, there are fewer examples of this practice in the development of digital endpoints using mobile sensor technology such as physical activity monitors. This study explored the utility of social media data, specifically, posts on online health boards, in understanding meaningful aspects of health related to physical activity in 3 different chronic diseases: fibromyalgia, chronic obstructive pulmonary disease, and chronic heart failure. METHODS: We used machine learning and manual coding to summarize the content of posts extracted from 4 online health boards. Where available, patient age and sex were retrieved from post content or user profiles. We utilized analytical approaches to assess the robustness of findings to differences in the characteristics of online samples compared to the true patient population. Finally, we assessed concept saturation by measuring the convergence of autocorrelations. RESULTS: We identify a number of aspects of health described as important by patients in our samples, and summarize these into concepts for measurement. For chronic heart failure, these included purposeful walking duration and speed, fatigue, difficulty going upstairs, standing, and aspects of physical exercise. Overall and age-adjusted results did not differ considerably for each disease group. CONCLUSIONS: This study illustrates the potential of performing concept elicitation research using social media data, which may provide valuable insight to inform COA development.
Subject(s)
Pulmonary Disease, Chronic Obstructive , Humans , Fatigue , Patient Reported Outcome Measures , Exercise , Machine LearningABSTRACT
Background: Computational approaches to support rare disease diagnosis are challenging to build, requiring the integration of complex data types such as ontologies, gene-to-phenotype associations, and cross-species data into variant and gene prioritisation algorithms (VGPAs). However, the performance of VGPAs has been difficult to measure and is impacted by many factors, for example, ontology structure, annotation completeness or changes to the underlying algorithm. Assertions of the capabilities of VGPAs are often not reproducible, in part because there is no standardised, empirical framework and openly available patient data to assess the efficacy of VGPAs - ultimately hindering the development of effective prioritisation tools. Results: In this paper, we present our benchmarking tool, PhEval, which aims to provide a standardised and empirical framework to evaluate phenotype-driven VGPAs. The inclusion of standardised test corpora and test corpus generation tools in the PhEval suite of tools allows open benchmarking and comparison of methods on standardised data sets. Conclusions: PhEval and the standardised test corpora solve the issues of patient data availability and experimental tooling configuration when benchmarking and comparing rare disease VGPAs. By providing standardised data on patient cohorts from real-world case-reports and controlling the configuration of evaluated VGPAs, PhEval enables transparent, portable, comparable and reproducible benchmarking of VGPAs. As these tools are often a key component of many rare disease diagnostic pipelines, a thorough and standardised method of assessment is essential for improving patient diagnosis and care.
ABSTRACT
The Global Alliance for Genomics and Health (GA4GH) Phenopacket Schema was released in 2022 and approved by ISO as a standard for sharing clinical and genomic information about an individual, including phenotypic descriptions, numerical measurements, genetic information, diagnoses, and treatments. A phenopacket can be used as an input file for software that supports phenotype-driven genomic diagnostics and for algorithms that facilitate patient classification and stratification for identifying new diseases and treatments. There has been a great need for a collection of phenopackets to test software pipelines and algorithms. Here, we present phenopacket-store. Version 0.1.12 of phenopacket-store includes 4916 phenopackets representing 277 Mendelian and chromosomal diseases associated with 236 genes, and 2872 unique pathogenic alleles curated from 605 different publications. This represents the first large-scale collection of case-level, standardized phenotypic information derived from case reports in the literature with detailed descriptions of the clinical data and will be useful for many purposes, including the development and testing of software for prioritizing genes and diseases in diagnostic genomics, machine learning analysis of clinical phenotype data, patient stratification, and genotype-phenotype correlations. This corpus also provides best-practice examples for curating literature-derived data using the GA4GH Phenopacket Schema.